Prothrombin
drugOn this page
Also known as Factor ii (prothrombin)Prothrombin component of balfaxar
Summary
Prothrombin (CHEMBL6068492) is an approved protein; indicated across 1 condition including blood coagulation disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Indications: 1 condition
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL6068492 |
| Name | Prothrombin |
| Type | Protein |
| Max phase | 4 |
Also known as: Factor ii (prothrombin), Prothrombin, Prothrombin component of balfaxar, PROTHROMBIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| blood coagulation disease | 4 | MONDO:0001531 | EFO:0009314 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE4 | 1 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06974396 | PHASE4 | NOT_YET_RECRUITING | Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage |
| NCT01471730 | PHASE3 | COMPLETED | The ZEro PLASma Trial (ZEPLAST): Avoidance of Fresh Frozen Plasma in Cardiac Surgery |
| NCT06705829 | Not specified | RECRUITING | Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time and Factorial Assays in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage. |
| NCT05183997 | Not specified | UNKNOWN | Verapamil in Supraclavicular Brachial Plexus Block |
| NCT05883891 | Not specified | COMPLETED | Prothrombin Time Predicts Steroid Response in Severe Alcoholic Hepatitis. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: blood coagulation disease